title: Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: a report from the EBMT Solid Tumour Registry.
abstract: The European BMT Solid Tumour Registry (EBMT-STR) received reports from 21 European transplant centers on 63 patients (50 Ewing's sarcomas and 13 peripheral neuroectodermal tumours) in first (n = 32) or second CR (n = 31) consolidated with megatherapy and BM and/or PSC rescue between December 1982 and November 1992. There were 31 males and 32 females with a median age of 12 years (range 1-30 years) at megatherapy. The median follow-up time since megatherapy is 4 years (range 1 month to 10 years), Thirty-two patients with metastatic disease at diagnosis (22 had metastases to the bone and/or bone marrow) and consolidated in CR1 reached an actuarial event-free survival (EFS) of 21% at 5 years. Thirty one patients in CR2 achieved an actuarial EFS of 32% at 5 years. Favourable outcome was limited to relapse patients with localised disease at initial diagnosis. Distant relapse had a more favourable prognosis than local failure. Analysis of the different megatherapy strategies could not identify a significantly superior approach, nor is there convincing evidence in favour of double graft procedures. From the above results it appears that consolidation treatment by megatherapy contributes to improved EFS rates in high-risk patients compared with historical experience. Major questions for the future to be addressed prior to randomised studies include agreement on the definition of high-risk patients and the most efficient megatherapy procedure.
authors.affiliation: St Anna Children's Hospital, Vienna, Austria.
authors.forename: R
authors.initials: R
authors.lastname: Ladenstein
authors.forename: C
authors.initials: C
authors.lastname: Lasset
authors.forename: R
authors.initials: R
authors.lastname: Pinkerton
authors.forename: J M
authors.initials: JM
authors.lastname: Zucker
authors.forename: C
authors.initials: C
authors.lastname: Peters
authors.forename: S
authors.initials: S
authors.lastname: Burdach
authors.forename: N
authors.initials: N
authors.lastname: Pardo
authors.forename: S
authors.initials: S
authors.lastname: Dallorso
authors.forename: C
authors.initials: C
authors.lastname: Coze
authors.forename: G
authors.initials: G
authors.lastname: Dollorso
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D001859:Bone Neoplasms / Q000401:mortality / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D009362:Neoplasm Metastasis; D012042:Registries; D012307:Risk Factors; D012512:Sarcoma, Ewing / Q000401:mortality / Q000628:therapy*; D016019:Survival Analysis